FDA PET guidance vacated by Federal appeals court; policy required formal rulemaking.
This article was originally published in The Gray Sheet
Executive SummaryFDA's PET GUIDANCE NEEDED PUBLIC NOTICE; AGENCY VIOLATED FEDERAL LAW, Washington, D.C. appeals court determines Oct. 28, reversing a district court summary judgment in Syncor International Corp., et al. v. Donna E. Shalala, et al. The lower court had found that although FDA's February 1995 guidance on positron emission tomography radiopharmaceuticals was not a guidance but an interpretive rule, it was not required to give notice of proposed rulemaking to the public ("The Gray Sheet" March 17, p. 9).
You may also be interested in...
At the end of the Brexit transition period, the UK will be charting its own course through the often choppy seas of medicines regulation. While it plans to retain the existing EU rules that have been transposed into domestic legislation, it also wants the freedom to tailor its regulations in areas like clinical trials, advanced therapies and product labeling.
Health technology assessment body NICE is consulting on draft guidance that recommends Axonics' device for overactive bladder.